Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion

Published on 16 Sep 2025
Last Updated on 16 Sep 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended aflibercept 2 mg/0.05 mL prefilled syringe and vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion.

The Ministry of Health’s Drug Advisory Committee has not recommended faricimab 6 mg/0.05 mL vial for treating adults with visual impairment due to macular oedema secondary to retinal vein occlusion, due to the unacceptable pricing proposal from the company.

Funding status

Aflibercept 2 mg/0.05 mL prefilled syringe and vial are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.

MAF assistance does not apply to faricimab, and other formulation(s) or strengths(s) of aflibercept for the abovementioned indication.

Aflibercept and faricimab for treating macular oedema secondary to retinal vein occlusion (Published 16 Sep 2025)